Division and Department

Department of Pharmacokinetics


Masatomo Miura, PhD

A Greeting from the Professor

In Department of Pharmacokinetics, we are specializing in clinical pharmacology, clinical pharmacokinetics, pharmacogenomics and analytical chemistry. We provide quality drug analysis services, analytical support and therapeutic drug monitoring (TDM) for clinician. Therapeutic drug monitoring (TDM) is a part of personalized (precision) medicine, and is defined as the management of a patient’s drug regime based on serum, plasma, or whole blood concentration of a drug. TDM is essential in order to achieve maximum efficacy of the drug as well as to avoid drug toxicity. We excel at developing new analysis method based on high-performance liquid chromatography to determine drug concentrations in blood. Clinically useful TDM does require that there is a good relationship between plasma concentration and clinical effect. We determine therapeutic target ranges indicating exposure-response (efficacy/toxicity) relationships.
Pharmacogenomics is also a part of precision medicine, which aims to tailor medical treatment to each person or to a group of people. Dose adjustment based on pharmacogenomics can improve efficacy and minimize side effects of drug treatments, resulting in better clinical outcomes and patient experiences. We determine the relationships between drug plasma concentration and drug single-nucleotide polymorphisms (SNPs) in drug metabolizing enzymes or transporters. The SNP-based approach and TDM in clinic make us confident of achieving one of our goals.

Staff

Professor:
Masatomo Miura, PhD

Research Areas

  1. Clinical pharmacology
  2. Clinical pharmacokinetics
  3. Pharmacogenomics
  4. Analytical chemistry
  5. Drug-drug/food (juice) interaction

Contact Information

Professor, Masatomo Miura, PhD
Phone: +81-18-884-6439
Fax: +81-18-884-6451
E-mail: [email protected]

Most Recent Achievements

  1. Fukuda N, Akamine Y, Abumiya M, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M. Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy. Cancer Chemother Pharmacol. 2022; 89: 609-616.
  2. Kumagai M, Nagahama M, Akamine Y, Ozeki T, Suzuki A, Sugino K, Ito K, Miura M. Associations Between Plasma Concentrations of Lenvatinib and Angiopoietin and Clinical Responses to Lenvatinib Therapy in Japanese Patients With Thyroid Cancer. Cancer Diagn Progn. 2022; 2: 336-344.
  3. Yagishita H, Kagaya H, Saito M, Numakura K, Yamamoto R, Sagehashi R, Habuchi T, Satoh S, Miura M. Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients. Int J Mol Sci. 2022; 23(19): 11742.
  4. Yokota H, Sato K, Sakamoto S, Okuda Y, Asano M, Takeda M, Nakayama K, Miura M. Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer. Biology (Basel). 2021; 10: 1054.
  5. Fujita K, Motoyama S, Sato Y, Wakita A, Nagaki Y, Minamiya Y, Miura M. Association between ABCC2 polymorphism and hematological toxicity in patients with esophageal cancer receiving platinum plus 5-fluorouracil therapy. Esophagus. 2022; 19: 146-152.
  6. Abumiya M, Takahashi N, Takahashi S, Yoshioka T, Kameoka Y, Miura M. Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy. Sci Rep. 2021; 11: 6362.

back